Company intelligence / Profile preview
JangoBio
Fitchburg, Wisconsin, United Statesjango.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
JangoBio has developed a regenerative medicine platform using stem cell-derived organoids to restore hormone balance by regenerating gonadal tissues. Their lead program "Jango-Renew" targets the veterinary market for age-related hormonal decline in pets. The company reports ongoing enrollment of a pilot veterinary clinical study with preliminary data expected late 2025. Human therapeutic programs remain at the preclinical stage.
- Therapeutic areas
- OtherEndocrinology
- Modalities
- Stem cell therapyOrganoid-based therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
None publicly disclosed as of June 2025.
Beyond the preview
Go deeper on JangoBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JangoBio.